Today: 17 May 2026
Coles share price today: COL.AX slips but beats ASX tumble as dividend date nears
4 March 2026
1 min read

Coles share price today: COL.AX slips but beats ASX tumble as dividend date nears

Sydney, March 4, 2026, 17:33 AEDT — Market closed

Coles Group Ltd (COL.AX) shares ended down 0.5% at A$21.25 on Wednesday, holding up better than the broader sell-off in Sydney. The stock traded between A$21.18 and A$21.71 and about 5.7 million shares changed hands, the company’s investor page showed.

The benchmark S&P/ASX 200 fell 1.94% to 8,901.20, keeping the mood defensive into the next session. Coles’ smaller drop stood out against that tape.

A firmer annual growth read at home and fresh oil-price volatility abroad are back in the same sentence, and that tends to drag rate expectations with it. Money markets kept bets of a March move at about 30% and fully priced in a hike for May, after the Middle East conflict disrupted oil flows through the Strait of Hormuz and pushed prices up more than 10%, according to a Reuters report.

Australia’s economy grew 0.8% in the December quarter and 2.6% from a year earlier, the Australian Bureau of Statistics said. “There was broad based economic growth in the quarter,” ABS head of National Accounts Grace Kim said. Australian Bureau of Statistics

Reserve Bank of Australia Governor Michele Bullock said this week the Middle East conflict was a reminder “things can change quickly” for the inflation outlook, and pointed to the cash rate at 3.85% as leaving policy well placed to respond. A supply shock could add to inflation, while a prolonged hit to energy markets could also hurt growth, she said. Reuters

Peer Woolworths Group finished down 0.96% at A$35.94, its investor site showed. Both supermarket names fell less than the index, a pattern that often shows up when traders are cutting risk.

For Coles, the week-ahead company marker is the interim dividend: 41.0 Australian cents a share, fully franked, with shares due to go ex-dividend on March 10. Ex-dividend means new buyers from that date will not receive the upcoming payout.

But the cushion is not guaranteed. If energy-driven inflation sticks and rates push higher, household budgets can tighten again and input costs can drift up at the same time, even for “defensive” retailers.

Next week’s lead items are overseas energy headlines and any further shift in Australian rate pricing ahead of the central bank’s March 16–17 meeting. That call, more than day-to-day volatility, is likely to set the tone for consumer names into mid-March.

Stock Market Today

  • Monster Beverage (MNST) Stock Near Fair Value After Multi-Year Gains
    May 16, 2026, 9:18 PM EDT. Monster Beverage (MNST) has delivered strong returns, rising nearly 89% over five years. The stock recently traded at around $87, modestly above its estimated intrinsic value of $80.02 based on a Discounted Cash Flow (DCF) model. This valuation approach projects Monster's free cash flow growing from $1.94 billion to over $3 billion by 2030. Despite impressive share price gains, the DCF suggests Monster is roughly 8.8% overvalued, indicating current prices are close to fair value rather than significantly overpriced. While the company's position in the US energy drink market supports growth prospects, its valuation score was 0 out of 6 on standard metrics, urging caution for new investors. Traders should monitor valuation shifts and market developments to time entries appropriately.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 04.03.2026

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform
Next Story

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform

Go toTop